| Market Capitalization (Millions $) |
3,851 |
| Shares
Outstanding (Millions) |
160 |
| Employees |
624 |
| Revenues (TTM) (Millions $) |
308 |
| Net Income (TTM) (Millions $) |
-64 |
| Cash Flow (TTM) (Millions $) |
34 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Adaptive Biotechnologies Corporation is a biotechnology company that specializes in the field of immune-driven medicine.
Founded in 2009 by Chad Robins and Harlan Robins, the Seattle-based company is focused on developing procedures and technologies to decode the immune system to help diagnose, manage, and treat various diseases.
Adaptive Biotechnologies' flagship product is its immune profiling technology, which uses next-generation sequencing and machine learning algorithms to read the genetic makeup of a patient's immune system.
This technology allows the company to develop highly personalized, targeted therapies for various types of cancers and autoimmune disorders.
The company has built a proprietary database of immune system data that is the largest and most diverse in the world.
This database is continuously growing through partnerships with biopharmaceutical companies and academic institutions.
Adaptive Biotechnologies also collaborates with researchers and physicians around the globe to advance the understanding of the immune system and develop new therapies.
Adaptive Biotechnologies has partnered with many pharmaceutical and biotech companies, such as Genentech and Amgen, to develop new diagnostic and therapeutic products.
The company has also received funding and investment from high-profile organizations such as Microsoft, which has invested in the company's technology for use in molecular diagnostics.
Some of the diseases that Adaptive Biotechnologies is exploring include cancer, autoimmune disorders, infectious diseases, and neurodegenerative diseases.
The company is also involved in developing COVID-19 testing products and has partnered with Microsoft to develop a blood-based test that can identify the immune response to the virus.
Adaptive Biotechnologies has received recognition for its innovative technology and research.
In 2019, the company was named a Technology Pioneer by the World Economic Forum, which honors companies that are using technology to solve global issues.
In summary, Adaptive Biotechnologies Corporation is a leading biotechnology company focused on developing innovative immune-driven technologies to diagnose, manage, and treat various diseases.
The company's immune profiling technology, proprietary database, and partnerships with biopharmaceutical companies and academic institutions have made it a leader in the field of immune-driven medicine.
Company Address: 1165 Eastlake Avenue East Seattle 98109 WA
Company Phone Number: 659-0067 Stock Exchange / Ticker: NASDAQ ADPT
|
1.57% 
173.66 %